Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2012, Article ID 517172, 7 pages
Research Article

CD24 Expression as a Marker for Predicting Clinical Outcome in Human Gliomas

Department of Neurosurgery, Institute for Functional Neurosurgery PLA, TangDu Hospital, Fourth Military Medical University, No. 1 Xinsi Road, Baqiao District, Xi’an 710038, China

Received 6 November 2011; Accepted 5 December 2011

Academic Editor: Xin-yuan Guan

Copyright © 2012 Jianping Deng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


CD24 is overexpressed in glioma cells in vitro and in vivo. However, the correlation of its expression with clinicopathological parameters of gliomas and its prognostic significance in this tumor remain largely unknown. To address this problem, 151 glioma specimens and 10 nonneoplastic brain tissues were collected. Quantitative real-time PCR, immunochemistry assay, and Western blot analysis were carried out to investigate the expression of CD24. As per the results, CD24 was overexpressed in gliomas. Its expression levels in glioma tissues with higher grade ( 𝑃 < 0 . 0 0 1 ) and lower KPS ( 𝑃 < 0 . 0 0 1 ) were significantly higher than those with lower grade and higher KPS, respectively. Cox multifactor analysis showed that CD24 ( 𝑃 = 0 . 0 2 ) was an independent prognosis factor for human glioma. Our data provides convincing evidence for the first time that the overexpression of CD24 at gene and protein levels is correlated with advanced clinicopathological parameters and poor prognosis in patients with glioma.